← Leaderboards
Govind Ragupathi
Sloan-Kettering Inst Can Research
$973,788
Attributed
$3,572,293
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2010–13$2M$1.5M$1M$500K$0
'10
'11
'12
'13
Funding mix
By agency
NIH$3,572,293 · 2
By mechanism
R01$3,423,141 · 1
R43$149,152 · 1
Top collaborators
- Samuel J Danishefsky4 shared
- Jason S Lewis4 shared
- Philip O. Livingston4 shared
- Brian H Kushner1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Jason S Lewis$26,024,327
- Pavel Nagorny$141,726
- Bryan James Cowen$98,932
Others in their field
Top investigators on “Saponins”
- Casey Koontz · Leidos, Inc.$11,293,734
- Bali Pulendran · Stanford University$8,058,918
- Robert Newton Brey · Dor Biopharma, Inc.$7,871,742
- Nicolas Collins · Vaccine Formulation Institute (Ch) Ltd$6,937,118
- David Burkhart · Inimmune Corporation$5,907,864
- Elizabeth Norton · Tulane University Of Louisiana$4,695,387
Research focus
SaponinsAdjuvantPreclinical StudyCancer VaccinesAntigensDoseImmunizationMalignant NeoplasmsSafetyVaccinesSaponinPreparationKeyhole Limpet HemocyaninImmunologic AdjuvantsBehaviorAuthorityAnimalsAttenuatedApplications GrantsAnalogAcuteCancer Vaccine Related DevelopmentAntiviral AgentsChemical Synthesis
Grant awards (5)
Novel Adjuvant Discovery in Vaccine Therapy$819,424
R01 · FY2013 · AI
Novel Adjuvant Discovery in Vaccine Therapy$871,728
R01 · FY2012 · AI
CONSTRUCTION AND TESTING OF A TRIVALENT VACCINE AGAINST NEUROBLASTOMA ADMINISTERE$149,152
R43 · FY2012 · CA
Novel Adjuvant Discovery in Vaccine Therapy$869,286
R01 · FY2011 · AI
Novel Adjuvant Discovery in Vaccine Therapy$862,703
R01 · FY2010 · AI